Orthofix International

Orthofix Medical, Inc. engages in the provision of medical devices. It operates through the following business segments: Global Spine and Global Extremities. The Global Spine reporting segment offers three primary product categories: Bone Growth Therapies, Spinal Implants, and Biologics. The Bone Growth Therapies product category manufactures, distributes, and provides support services of bone growth stimulator devices that enhance bone fusion. The Spinal Implants product category designs, develops, and markets a broad portfolio of motion preservation and fixation implant products used in surgical procedures of the spine. The Biologics product category provides a portfolio of regenerative products and tissue forms that allow physicians to treat a variety of spinal and orthopedic conditions. The Global Extremities reporting segment offers products and solutions that allow physicians to successfully treat a variety of orthopedic conditions unrelated to the spine. The company was founded on October 19, 1987 and is headquartered in Lewisville, TX.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Orthofix and SeaSpine post mixed Q4 results, eye synergies and growth

SeaSpine and Orthofix reported mixed Q4 performances but demonstrated overall revenue growth for the full year, with positive revenue guidance for 2023.
The merger synergies and product demand strengths are key highlights, while challenges in profitability and regulatory hurdles in Europe require attention.
Opportunities lie in integration efforts, cost efficiencies, and exploring new markets, indicating a strategic growth trajectory for the combined entity.
The upcoming Analyst Teach-In event and focus on operational planning underscore the commitment to transparency and strategic alignment post-merger.

Orthofix reports robust Q1 earnings, raises full-year revenue guidance

Orthofix International's Q1 2023 earnings call highlighted strong financial performance, strategic initiatives, and raised revenue guidance, underscoring growth prospects.
The company's focus on operational efficiency, product categories, and profitability signals a resilient business strategy amidst market challenges and competitive landscape.
With a robust financial foundation, Orthofix is well-positioned to navigate challenges, capitalize on growth opportunities, and drive sustainable value creation for shareholders.

Orthofix International reports robust Q2 earnings and growth outlook

Orthofix International delivered a strong Q2 performance, with notable revenue growth and positive outlook for 2023.
Efforts to integrate merged businesses are yielding results, with a focus on revenue enhancement and operational streamlining.
Challenges such as cash flow and supply chain disruptions are being addressed through strategic investments and operational improvements.
The company's focus on growth, efficiency, and strategic partnerships positions it well for future success and value creation.

Orthofix reports robust Q3 revenue growth, eyes profitability and stability

Orthofix International demonstrated strong revenue growth and market performance in Q3 2023, driven by successful product lines and strategic initiatives.
While facing challenges such as cash flow outflows and margin adjustments, the company remains focused on profitability and financial stability.
Opportunities lie in sustaining positive momentum, achieving cash flow positivity in 2024, and leveraging growth prospects through product innovation and market expansion.

Orthofix reports robust Q4 earnings, eyes growth in key segments

Orthofix International's Q4 2023 earnings call highlighted strong financial performance, strategic initiatives, and growth in key segments.
The company's focus on market share, distributor relationships, and portfolio enhancements positions it well for future success.
Despite challenges in a competitive landscape, Orthofix remains optimistic about growth opportunities and aims for continued innovation and collaboration.

Orthofix International reports robust Q1 earnings and raises 2024 guidance

Orthofix International (OFIX) delivered a strong Q1 2024 performance, focusing on growth, innovation, and operational efficiency. The company showcased revenue growth, margin expansion, and strategic priorities for the year. Challenges include sustaining growth in competitive markets and optimizing operational aspects, while opportunities lie in leveraging technology and talent for further growth.

Orthofix International reports strong Q2 performance and outlines growth strategies

Orthofix International's Q2 performance reflects solid revenue growth and margin expansion, supported by new product releases and operational efficiency.
While facing challenges in cash flow optimization, the company's strategic focus on innovation and synergies positions it well for future growth.
Opportunities in technology investment, cross-selling, and distribution enhancements offer avenues for Orthofix International to drive sustained growth and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Orthofix (OFIX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Orthofix (OFIX) Soars 6.4%: Is Further Upside Left in the Stock?

NEW YORK , Oct. 12, 2023 /PRNewswire/ -- Wolf Haldenstein Adler Freeman & Herz LLP ("Wolf  Haldenstein"), a preeminent national shareholder rights litigation firm, announces that is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or the "Company") (NASDAQ: OFIX). A ll investors who purchased shares and incurred losses are  advised  to contact the firm immediately at classmember@whafh.com or (800) 575-0735 or (212) 545-4774.

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against Orthofix Medical Inc.

NEW YORK , Oct. 7, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Orthofix Medical Inc. (NASDAQ: OFIX) resulting from allegations that Orthofix may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Orthofix securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

OFIX LOSS ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Orthofix Medical Inc. Investors to Inquire About Securities Class Action Investigation - OFIX

NEW YORK , Sept. 27, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Orthofix Medical Inc. (NASDAQ: OFIX) resulting from allegations that Orthofix may have issued materially misleading business information to the investing public.

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Orthofix Medical Inc. Investors to Inquire About Securities Class Action Investigation - OFIX

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Orthofix Medical Inc. (NASDAQ: OFIX) resulting from allegations that Orthofix may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Orthofix securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangem.

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Orthofix Medical Inc. Investors to Inquire About Securities Class Action Investigation – OFIX

According to Orthofix (OFIX), with the launch of the Galaxy Fixation Gemini system surgeons now have efficient solutions for lower extremity trauma scenarios where time is an important factor.

Orthofix (OFIX) Unveils Gemini System, Advances in Trauma Wing

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of Orthofix Medical Inc. (“Orthofix” or the “Company”) (NASDAQ: OFIX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Orthofix investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit you.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Orthofix Medical Inc. (OFIX) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / September 19, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Orthofix Medical Inc. and Encourages Investors with Losses In Excess of $500,000 to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of Orthofix Medical Inc. (“Orthofix” or the “Company”) (NASDAQ: OFIX) investors concerning the Company's possible violations of federal securities laws. On September 12, 2023, before the market opened, Orthofix disclosed that its Board's independent directors made the unanimous decision to terminate for cause Keith Valentine, John Bostjancic and Patrick Keran from their roles as Chief Executive.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Orthofix Medical Inc. (OFIX) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)-- #A--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Orthofix Medical Inc. (“Orthofix” or the “Company”) (NASDAQ: OFIX) on behalf of Orthofix stockholders. Our investigation concerns whether Orthofix has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On September 12, 2023, before the market opened, Orthofix disc.

ORTHOFIX ALERT: Bragar Eagel & Squire, P.C. is Investigating Orthofix Medical Inc. on Behalf of Orthofix Stockholders and Encourages Investors to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Orthofix Medical Inc. (“Orthofix” or the “Company”) (NASDAQ: OFIX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Orthofix investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securiti.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Orthofix Medical Inc. (OFIX) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / September 14, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Orthofix Medical Inc. and Encourages Investors with Losses In Excess of $250,000 to Contact the Firm

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Orthofix Medical Inc. (“Orthofix” or the “Company”) (NASDAQ: OFIX) investors concerning the Company's possible violations of federal securities laws. On September 12, 2023, before the market opened, Orthofix disclosed that its Board's independent directors made the unanimous decision to terminate for cause Keith Valentine, John Bostjancic and Patrick Keran from their roles as Chief Executive O.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Orthofix Medical Inc. (OFIX) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / September 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASDAQ:OFIX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Orthofix Medical Inc. and Encourages Investors with Losses to Contact the Firm

MILWAUKEE , Sept. 13, 2023 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Orthofix (NASDAQ: OFIX).

Ademi LLP Investigates Claims of Securities Fraud against Orthofix Medical Inc.

All three fired executives came over late last year in the merger with SeaSpine. Chairman of the Board Catherine Burzik is stepping in as the interim CEO.

Why Shares of Orthofix Medical Are Plummeting on Tuesday

Shares of Orthofix Medical Inc. OFIX, +1.42% plunged 17.1% toward a 10-month low in premarket trading Tuesday, after the spine and orthopedics company said it terminated Chief Executive Keith Valentine, Chief Financial Officer John Bostjancic and Chief Legal Officer Patrick Keran “for cause,” effective immediately. The terminations follow a investigation conducted by independent counsel.

Orthofix terminates CEO, CFO and CLO for repeated ‘offensive conduct,' and stock plunges

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ: OFIX), a leading global spine and orthopedics company, today announced that Catherine Burzik, Chair of the Orthofix Board of Directors, has been appointed Interim Chief Executive Officer; Geoffrey Gillespie, Orthofix Vice President, Corporate Controller, has been appointed Interim Chief Financial Officer; and Puja Leekha, Orthofix Senior Vice President, Chief Ethics and Compliance Officer, has been appointed Interim Chief Legal.

Orthofix Announces Leadership Changes

After reaching an important support level, ORTHOFIX MEDICAL INC. (OFIX) could be a good stock pick from a technical perspective.

Should You Buy Orthofix (OFIX) After Golden Cross?

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that the Company will participate in the Morgan Stanley Healthcare Conference in New York City. Management is scheduled to present on Tuesday, September 13, 2023 at 1:35 p.m. ET. Interested parties can access the live and archived webcast of the presentation on the Investors section of the Orthofix website at ir.orthofix.com. About Orthofix: On January 5, 2023.

Orthofix to Participate in Morgan Stanley Healthcare Conference

Orthofix (OFIX) announces the commercial launch and the successful completion of the first cases in the United States with the 7D FLASH Navigation System Percutaneous Module 2.0.

Orthofix's (OFIX) New Launch to Benefit the MIS Spine Market

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global spine and orthopedics company, today announced that the company will host an Investor Day at the Lewisville, TX headquarters on Wednesday, September 20, 2023 at 1:00pm Central Time. A live and archived webcast of the presentations will be available on the Investor's page of the company's website at ir.Orthofix.com. In-person attendance at the event requires advanced registration. Please email Louisa Smith.

Orthofix Medical to Host Investor Day on September 20, 2023

Orthofix Medical Inc. (NASDAQ:OFIX ) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Louisa Smith - Vice President of Investor Relations, Gilmartin Group LLC Keith Valentine - Chief Executive Officer John Bostjancic - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel Financial Corp. Jeffrey Cohen - Ladenburg Thalmann & Co. Inc. David Turkaly - JMP Group LLC Operator Ladies and gentlemen, good afternoon. My name is Abby, and I will be your conference operator today.

Orthofix Medical Inc. (OFIX) Q2 2023 Earnings Call Transcript

Orthofix (OFIX) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.67 per share. This compares to earnings of $0.08 per share a year ago.

Orthofix (OFIX) Q2 Earnings and Revenues Surpass Estimates

LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX) today reported its financial results for the quarter ended June 30, 2023. Net sales were $187.0 million, earnings per share (“EPS”) was $(1.07), and adjusted EPS was $0.02. “I am very pleased with Orthofix's performance this quarter, delivering 7% year-over-year growth, on a proforma basis, and once again achieving double-digit growth in the Bone Growth Therapies franchise,” said Keith Valentine, President and Chief Executi.

News for Orthofix International Stock (OFIX)